Q-omics provides the consensus-scored SBK3 profile across patient tissues and cancer cell-line models. SBK3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, SBK3 is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, SBK3 RNA expression shows 16,779 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight SCLC, KICH, and KIRP as cancer lineages where SBK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SBK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SBK3 survival associations across molecular data types. SBK3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SBK3 RNA expression–survival associations across cancer types. High SBK3 expression shows unfavorable associations in LGG, CESC, LUSC and LIHC, but favorable associations in SCLC and SKCM. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for SBK3 RNA expression.
This table summarizes SBK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for SBK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SBK3 shows lower tumor expression in KICH and BRCA and higher tumor expression in LIHC, STAD, CHOL and LUAD. The KICH box plot shows higher SBK3 RNA expression in normal versus tumor tissue (log2 FC = −0.451, t-test p < 0.001).
This table shows molecular features associated with SBK3 in patient tissues and cancer cell lines. In patient samples, SBK3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SBK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and SKIN.
